Clinical trial
Effect of Alpha-Lipoic Acid as Add-on Therapy to Dapagliflozin on Insulin Resistance and Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
NCT07934225 is registered in ClinicalTrials.gov with Fayoum University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Alpha-Lipoic Acid as Add-on Therapy to Dapagliflozin on Insulin Resistance and Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- Lead sponsor
- Fayoum University
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- December 1, 2026
- Completion date
- September 1, 2027
- Enrollment
- 70 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
diabetes mellitus, type 2, insulin resistance syndrome
Arms
As registered; 2 arms.
-
ALA + Metformin/Dapagliflozin
Alpha-lipoic acid 600 mg capsule taken orally once daily for 12 weeks, in addition to the participant's usual metformin and dapagliflozin 10 mg daily, which continue unchanged.
-
Placebo + Metformin/Dapagliflozin
Matching placebo capsule taken orally once daily for 12 weeks, in addition to the participant's usual metformin and dapagliflozin 10 mg daily, which continue unchanged.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
HOMA-IR = fasting insulin (microunits/mL) x fasting glucose (mg/dL) / 405, calculated from fasting blood samples. Change = Week 12 value minus baseline value.
Lead sponsor's other trials
Fayoum University, most recent start first.
+143 more trials See the organization page
Similar trials
Same condition (Metabolic Syndrome) and phase, most recent start first.
+66 more trials See the condition page